We also confirmed that a novel aminothiazole TNIK inhibitor, KY-05009 (5-(4-methylbenzamido)-2-(phenylamino) thiazole-4-carboxamide), has high affinity for the ATP binding site of TNIK and pharmacologically inhibits transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells [12]. This evidence concerns the gene TNIK and lung adenocarcinoma.